Roth/MKM reiterates Buy rating on Sequans stock, $20 target

Roth/MKM reiterates a Buy on Sequans with a $20 price target versus the current $3.22 share price, implying >520% upside. Sequans reported Q4 2025 revenue growth but a net loss, trades at a Price/Book of 0.23 and is noted as deeply discounted to an ~ $5/share net asset value after an 85% decline over the past year. Management targets cash-flow breakeven by end-2026 and IoT operating business aims for H1 2027 break-even with Cat 1bis momentum; an ongoing buyback could add roughly $0.50 in NAV per 10% repurchased, supporting the firm's bullish view.

Analysis

Sequans' strategy to monetize IP around eRedCap/RedCap creates asymmetric ecosystem effects: module and module-ODM suppliers (Quectel/Fibocom equivalents) stand to shorten time-to-market and can capture incremental margin via licensing amortization, while legacy baseband incumbents face margin erosion if they must lower price to retain design-ins. A successful licensing roll-out will also shift who negotiates with foundries — small, high-volume IoT wafters will compete for low-cost node allocation, tightening capacity for other niche IoT silicon players and raising BOM timing risk for module makers.

Key catalysts cluster into two buckets: commercialization events (signed licensing agreements, public OEM design-ins) that can re-rate sentiment within quarters, and financial housekeeping (proof of positive operating cash flow) that will matter on a 6–18 month horizon. Tail risks include execution slippage on licensing deals, forced dilutive financing if cash burn persists, and a multi-player standard fight where a rival with deeper channel relationships or subsidized modules undercuts pricing; any one of these can turn the current asymmetric upside into a binary loss.

The market consensus appears to prize optionality more than rate-of-adoption; that understates runway and concentration risk. Buybacks mechanically lift NAV per share, but their benefit is highly non-linear and can be reversed by even a single dilutive financing or a major customer revenue shortfall. Treat this as a binary, event-driven micro-cap opportunity — size small, time-limited, and hedge aggressively rather than buying outright conviction exposure.

Key Decisions for Investors

• Small asymmetric long: allocate 1–2% portfolio to SQNS equity as a binary option on licensing/decoder wins; hold 6–12 months, trim if no material commercial update in two consecutive quarters. Risk/reward: potential >3x on successful OEM licensing runs vs concentrated downside if financing needed; use 50% stop-loss on position size to limit tail risk.
• Defined-risk options spread: buy 12-18 month call spread on SQNS (long a deep-OTM 12m call at ~150–200% of current level, short a higher strike at ~300–400%) to capture re-rate while capping premium. This yields 2–3x upside on a limited premium outlay and limits theta decay compared with naked calls.
• Pair trade to isolate execution risk: go long SQNS / short UBX (u-blox) equal notional for 12 months to isolate company-specific execution on licensing; size 0.5–1% net long. If Sequans wins licensing deals without market-wide IoT re-rating, this should outperform; unwind if UBX reports meaningful share-loss evidence.
• Tail protection: buy 9–12 month put protection equal to ~25% of the long exposure (or purchase a put spread to reduce cost) to cap downside from dilution or a lost major customer. This keeps the asymmetric payoff while limiting cash-at-risk if the operational story deteriorates.